

Supplement 5. Comparison of the DR-related vision impairment estimates between our study and the Visual Loss Expert Group (VLEG) / Global Burden of Disease Study (GBD).

1. Comparison with region-level estimates

VLEG/GBD*	Age-standardized population prevalence (‰), 2020			
	All age		Age 50+	
	MSVI	Blindness	MSVI	Blindness
High-income	0.168	0.075	0.665	0.254
Asia Pacific				
East Asia	0.418	0.107	1.805	0.385
Our study	Age 20+		Age 55+	
	MSVI	Blindness	MSVI	Blindness
Taiwan	0.586	0.087	1.606	0.198


DR, diabetic retinopathy; VLEG, Vision Loss Expert Group; GBD, Global Burden of Disease Study; MSVI, moderate and severe vision impairment

* Data was obtained from the VLEG/GBD 2020 model through Vision Atlas on the International Agency for the Prevention of Blindness (IAPB) website:

1. Bourne R, Steinmetz J, Flaxman S, et al., Trends in prevalence of blindness and distance and near vision impairment over 30 years: an analysis for the Global Burden of Disease Study. Lancet Glob Health. 2020. Accessed via the IAPB Vision Atlas (<https://www.iapb.org/learn/vision-atlas>)
2. Adelson, J., Bourne, R. R. A., Briant, P. S., Flaxman, S., Taylor, H., Jonas, J. B., et al., Causes of blindness and vision impairment in 2020 and trends over 30 years, and prevalence of avoidable blindness in relation to VISION 2020: the Right to Sight: an analysis for the Global Burden of Disease Study. Lancet Global Health. 2020. Accessed via the IAPB Vision Atlas (<https://www.iapb.org/learn/vision-atlas>)

2. Comparison with country-level estimates

Vision impairment caused by diabetic retinopathy in Taiwan, 2019



We obtained the age-specific number of DR-related vision impairment in Taiwan estimated by GBD 2021 from the GBD Results Tool:

Global Burden of Disease Collaborative Network.

Global Burden of Disease Study 2021 (GBD 2021) Results.

Seattle, United States: Institute for Health Metrics and Evaluation (IHME), 2022.

Available from <https://vizhub.healthdata.org/gbd-results/>.